Active Juvenile Idiopathic Arthritis (JIA) Compassionate Use

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier:
NCT00775437
First received: October 17, 2008
Last updated: December 17, 2015
Last verified: December 2015
  Purpose
The main objective of this study is to evaluate the safety of adalimumab in patients 2 to < 4 years of age or ≥ 4 years of age weighing < 15 kg, with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) or polyarticular course JIA.

Condition Intervention Phase
Juvenile Idiopathic Arthritis
Drug: Adalimumab
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Compassionate Use Study of Adalimumab in Children 2 to < 4 Years Old or Age 4 and Above Weighing Less Than 15 kg With Active Juvenile Idiopathic Arthritis (JIA)

Resource links provided by NLM:


Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Number of Participants With Treatment-Emergent Adverse Events (TEAEs) [ Time Frame: TEAEs were collected from first dose of study drug until 70 days after the last dose of study drug and before start of commercial adalimumab or other biologics (32.5 months). ] [ Designated as safety issue: Yes ]
    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. If an AE meets any of the following criteria, it is considered a serious adverse event (SAE): Results in death, is life-threatening, results in hospitalization or the prolongation of hospitalization, is a congenital anomaly or a persistent or significant disability/incapacity, or is an important medical event requiring medical or surgical intervention to prevent a serious outcome. A treatment-emergent AE (TEAE) is defined as any AE with onset or worsening reported by a participant from the time that the first dose of adalimumab is administered until 5 half-lives (70 days) have elapsed following discontinuation of adalimumab administration (total of 32.5 months).


Secondary Outcome Measures:
  • Mean Serum Adalimumab Trough Concentrations at Week 0, Week 12, and Week 24 [ Time Frame: Weeks 0, 12, and 24 ] [ Designated as safety issue: No ]
    Adalimumab concentrations in serum were determined using a validated enzyme-linked immunoadsorbent assay (ELISA) method. The lower limit of quantitation (LLOQ) for adalimumab is 3.13 ng/mL.

  • Hemoglobin: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Hematocrit: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Red Blood Cell (RBC) Count: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Platelets: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • White Blood Cell (WBC) Count: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Neutrophils: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Lymphocytes: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Monocytes: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Eosinophils: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Basophils: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Alanine Aminotransferase (SGPT/ALT): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Aspartate Aminotransferase (SGOT/AST): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug.Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Alkaline Phosphatase (ALP): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Creatine Phosphokinase: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Total Bilirubin: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Creatinine: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Uric Acid: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Baseline is the last value prior to the first dose of study drug. Participants with non-missing baseline and at least 1 post-baseline observation are included in the analysis. n=participants with evaluable data at given time point.

  • Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 30% Response (PedACR30) [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The PedACR30 response is defined by the PedACR as ≥30% improvement in at least 3 of 6 JIA core set criteria, and ≥30% worsening in ≤1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria are Physician's Global Assessment (PGA) of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with loss of passive motion [LOM] and joints with pain on passive motion [POM], tenderness, or both), number of joints with LOM, Disability Index of Child Health Assessment Questionnaire (DICHAQ), and C-reactive protein (CRP). Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using last observation carried forward (LOCF) and non-responder imputation (NRI); observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

  • Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 50% Response (PedACR50) [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The PedACR50 response is defined by the PedACR as ≥ 50% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

  • Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 70% Response (PedACR70) [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The PedACR70 response is defined by the PedACR as ≥ 70% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

  • Percentage of Participants Achieving Pediatric American College of Rheumatology (PedACR) 90% Response (PedACR90) [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The PedACR90 response is defined by the PedACR as ≥ 90% improvement in at least 3 of 6 JIA core set criteria, and ≥ 30% worsening in not more than 1 of 6 JIA core set criteria. The 6 variables for the JIA core set criteria include PGA of participant's disease activity, Parent's Global Assessment of participant's disease activity, number of active joints (joints with swelling not due to deformity or joints with LOM and joints with POM, tenderness, or both), number of joints with LOM, DICHAQ, and CRP. Baseline is the last value prior to the first dose of study drug. Missing data were imputed up to Week 60 using LOCF and by NRI; observed values are presented for timepoints past Week 60. n=number of participants for either observed or imputed methods at given time point.

  • Physician's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The physician's assessment of participant's overall disease activity on a visual analog scale (VAS). The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Parent's Global Assessment of Disease Activity: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The parent's assessment of how the participant's arthritis is doing overall on a VAS. The VAS is a 100 mm scale, with scores ranging from 0 (very good) to 100 (very bad). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Disability Index of Child Health Assessment Questionnaire (DICHAQ): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The DICHAQ is a self-reported participant-oriented outcome measure, calculated as the mean of the following 8 category scores (range: 0 to 3): Dressing and Grooming, Arising, Eating, Walking, Hygiene, Reach, Grip, and Activities. The score of each category is calculated as the maximum of the scores for the questions within that category. If aids and devices and/or help from another person are used for a category, a lower category score is adjusted to 2 for that category. A participant must have scores for at least 6 categories in order to compute the DICHAQ score. Total score is derived as average of all categories: 0 (no disability) to 3 (complete disability). Baseline is the last value prior to the first dose of study drug. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Active Joint Counts (AJC73): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    A joint assessment was recorded at all study visits to assess the number of active joints, with a total possible score of 0 (no active joints) to 73 (all active joints). Active joints are defined as joints with positive results for tenderness, swelling, pain on passive motion, or limitation of passive motion. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Limitation of Passive Motion (LOM69) Joint Count: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Sixty-nine joints were assessed by physical examination. The joints to be examined for LOM were the same as those examined for tenderness, except that the sacroiliac, sternoclavicular, and acromio clavicular joints were excluded. LOM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 621, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • C-reactive Protein (CRP): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    CRP is a laboratory parameter and considered as an efficacy variable. CRP is a general marker of inflammation that is sensitive to acute changes in inflammatory response. CRP is reported using mg/dL. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Tender Joint Count (TJC75): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Seventy-five joints or regions were assessed by pressure and joint manipulation on physical examination. Joint tenderness was classified as either present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Swollen Joint Count (SJC66): Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Sixty-six joints were assessed by physical examination. The joints to be examined for swelling were the same as those examined for tenderness, except that the hip, subtalar, sacroiliac, lumbar spine, thoracic spine, and cervical spine joints were excluded. Joint swelling was classified as present ("1"), absent ("0") or replaced/injected ("9"). Scores range from 0 to 594, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Pain on Passive Motion (POM75) Joint Count: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 2, 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    Seventy-five joints were assessed by physical examination. The joints to be examined for POM were the same as those examined for tenderness. POM of the joint was classified as present ("1"), absent ("0"), or replaced/injected ("9"). Scores range from 0 to 675, with higher scores representing higher disease activity. Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Global Health Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Physical Functioning Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120. ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations/Emotional/Behavioral Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Role/Social Limitations - Physical Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Bodily Pain/Discomfort Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Behavior Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Global Behavior Item: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Mental Health Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Self Esteem Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) General Health Perceptions Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Change in Health Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Emotional Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Parental Impact - Time Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Family Activities Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.

  • Child's Health Questionnaire Parent Form (CHQ-PF50) Family Cohesion Category: Mean Change From Baseline to Each Visit [ Time Frame: Baseline and Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, and 120 ] [ Designated as safety issue: No ]
    The CHQ-PF50 is a participant-reported outcome measure that includes 50 questions related to physical and mental health, social limitations, and impact on parents and family. Scores for each category were converted to a scale from 0 (implies higher disease activity) to 100 (implies lower disease activity). Baseline is defined as the last nonmissing value prior to the first dose of study drug. Participants with nonmissing Baseline and at least 1 postbaseline observation are included in the analysis. n=participants with a nonmissing value at baseline and each visit.


Enrollment: 32
Study Start Date: March 2009
Study Completion Date: March 2013
Primary Completion Date: March 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Adalimumab
Adalimumab 24 mg/m^2 body surface area (BSA) up to a total dose of 20 mg administered every other week (eow) by parent or designee as a single dose via subcutaneous injection at approximately the same time of day, for a minimum of 24 weeks. Participants could continue in the study until age 4 and 15 kg (US and Puerto Rico) or for up to 1 additional year after reaching age 4 and 15 kg (EU). Visits beyond Week 24 occurred every 12 weeks for those participants who continued in the study.
Drug: Adalimumab
Adalimumab solution for injection for subcutaneous use.
Other Names:
  • Humira
  • ABT-D2E7

  Eligibility

Ages Eligible for Study:   2 Years to 4 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. A parent or guardian has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board (IRB)/Independent Ethics Committee (IEC), after the nature of the study has been explained and the subject's parent or legal guardian has had the opportunity to ask questions. The informed consent must be signed before any study-specific procedures are performed or before any medication is discontinued for the purpose of this study. The parent must also be willing to comply with all the requirements of this study protocol.
  2. Subject has a disease diagnosis of moderately to severely active polyarticular or polyarticular course juvenile idiopathic arthritis (JIA; defined as arthritis affecting > = 5 joints at the time of treatment initiation). This corresponds to the International League of Associations for Rheumatology categories of polyarticular rheumatoid factor positive (RF+), polyarticular Rheumatoid factor negative (RF-) disease, and extended oligoarthritis disease.
  3. Subject must be aged 2 to < 4 years old with moderately to severely active polyarticular JIA or polyarticular course JIA or age 4 or greater weighing < 15 kg with moderately to severely active polyarticular JIA or polyarticular course JIA, per International League of Associations for Rheumatology (ILAR) criteria.
  4. Subject is judged to be in generally good health as determined by the Investigator based upon the results of medical history, laboratory profile, and physical examination performed at Screening and confirmed at Baseline. This includes, but is not limited to, a normal cardiopulmonary and normal neurological exam result.
  5. Parent or legal guardian must be able and willing to administer subcutaneous (SC) injections or have a qualified person available to administer SC injections.
  6. Parent or legal guardian must be willing to actively supervise storage and administration of study drug and to ensure that the time of each dose is accurately recorded in the subject's diary.
  7. Subject must have negative purified protein derivative (PPD) test (or equivalent) at Screening. If subject has a positive (greater than or equal to 5mm induration) PPD test result, a chest x-ray (posterior-anterior [PA] and lateral view) must be performed. If subject has a positive test (or equivalent), has had a past ulcerative reaction to PPD placement, and/or a chest x ray consistent with tuberculosis [TB] exposure, subject may not be enrolled into the study.
  8. For subjects in the European Union [EU], subject must have previously failed, had an insufficient response, or have been intolerant to at least one Disease-Modifying Anti Rheumatic Drug (DMARD).

Exclusion Criteria:

  1. Subject has had prior exposure to Tysabri® (natalizumab) or Raptiva® (efalizumab) or any other biologic therapy, such as Orencia® (abatacept), Kineret® (anakinra), Actemra® (tocilizumab), Rituxan® (rituximab). Any previous use of anti-tumor necrosis factor [TNF] agents, including Enbrel® (etanercept), Remicade® (infliximab), Cimzia® (certolizumab pegol), Simponi® (golimumab), and adalimumab is also prohibited.
  2. Infection(s) requiring treatment with intravenous (IV) anti-infectives within 30 days prior to Baseline Visit or oral anti-infectives within 14 days prior to the Baseline Visit.
  3. Subject has undergone joint surgery within the preceding two months of the Screening Visit (at joints to be assessed within the study).
  4. Subject has a previous diagnosis of a condition that could cause arthritis other than polyarticular JIA.
  5. Subject has a history of an allergic reaction or significant sensitivity to constituents of the study drug, adalimumab.
  6. Subject has been treated with any investigational drug of chemical or biologic nature within a minimum of 30 days or 5 half lives (whichever is longer) of the drug prior to Baseline visit. Should these biologics become approved, they would continue to be excluded.
  7. Subject has a poorly controlled medical condition, such as uncontrolled diabetes, unstable heart disease, recent cerebrovascular accidents, seizure disorder, and any other condition which, in the opinion of the Investigator, would put the subject at risk by participation in the study.
  8. Subject has a history of clinically significant hematologic (e.g., severe anemia, leukopenia, thrombocytopenia, a clotting disorder), renal, liver disease (e.g., fibrosis, cirrhosis, hepatitis), or active gastroenteric ulcer.
  9. Subject is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.
  10. Subject has evidence of active TB infection.
  11. Subject has history of moderate to severe congestive heart failure (New York Heart Association [NYHA] class III or IV), recent cerebrovascular accident or thrombotic event and any other condition which, in the opinion of the investigator, would put the subject at risk by participation in the protocol.
  12. Evidence of dysplasia or history of malignancy (including lymphoma and leukemia).
  13. History of demyelinating disease (including myelitis) or neurologic symptoms suggestive of central nervous system [CNS] demyelinating disease.
  14. History of invasive fungal infection (e.g., listeriosis, histoplasmosis), active viral disorders, human immunodeficiency virus (HIV) infection.
  15. Positive Hepatitis B test result.
  16. Chronic recurring infections or active TB.
  17. Screening laboratory and other analyses show any of the following abnormal results:

    • electrocardiogram [ECG] - with clinically significant abnormalities;
    • Aspartate transaminases (AST) or alanine transaminase (ALT) > 1.75 the upper limit of the reference range;
    • Total bilirubin >=3 mg/dL;
    • Serum creatinine > 1.6 mg/dL (convert to mmol/L).
  18. Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than a successfully treated non-metastatic cutaneous squamous cell or basal cell carcinoma.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00775437

Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Investigators
Study Director: Aileen L. Pangan, MD AbbVie
  More Information

Additional Information:
No publications provided by AbbVie

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: AbbVie ( AbbVie (prior sponsor, Abbott) )
ClinicalTrials.gov Identifier: NCT00775437     History of Changes
Other Study ID Numbers: M10-444  2009-013091-40 
Study First Received: October 17, 2008
Results First Received: December 17, 2015
Last Updated: December 17, 2015
Health Authority: Sweden: Medical Products Agency
Czech Republic: State Institute for Drug Control
Denmark: Ministry of Health
United States: Food and Drug Administration
Spain: Ministry of Health
Denmark: Danish Medicines Agency
Sweden: The National Board of Health and Welfare
Germany: Ministry of Health
Slovakia: State Institute for Drug Control
France: Afssaps - Agence francaise de securite sanitaire des produits de sante (Saint-Denis)

Keywords provided by AbbVie:
juvenile idiopathic arthritis
compassionate use
open label

Additional relevant MeSH terms:
Arthritis
Arthritis, Juvenile
Autoimmune Diseases
Connective Tissue Diseases
Immune System Diseases
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Adalimumab
Anti-Inflammatory Agents
Antirheumatic Agents
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on February 04, 2016